Intellia Therapeutics Inc

NTLA

NASDAQ. Currency in USD

45.80 -5.66 ( -11.00% )

Real time prices: December 01

Market Cap.
3.60B
Beta (5Y monthly)
1.83
Price/Earnings
-
EPS (TTM)
-5.87
Forward Dividend
0.00 (0.00%)
Ex-Dividend Date
Volume
5.46M
1y Target Est.
110.92
Day's Range
45.45
-
48.00
52 Week's Range
37.08
-
130.33

Historical Summary

Performance
EPS growth
Share Buybacks

About Intellia Therapeutics Inc

Sector
Healthcare
Industry
Biotechnology
Website
https://www.intelliatx.com
Exchange
NASDAQ (XNAS)
Shares Outstanding
68.15M
Employees
485
Address
40 Erie Street, Cambridge, MA, United States, 02139
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemophilia A and hemophilia B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency. Its ex vivo pipeline includes NTLA-5001 for the treatment of acute myeloid leukemia; and proprietary programs focused on developing engineered cell therapies to treat various oncological and autoimmune disorders. In addition, it offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. Intellia Therapeutics, Inc. has license and collaboration agreements with Novartis Institutes for BioMedical Research, Inc. to engineer hematopoietic stem cells for the treatment of sickle cell disease; Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; Ospedale San Raffaele; and a strategic collaboration with SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases. The company was formerly known as AZRN, Inc. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Latest news

Intellia Therapeutics Announces Pricing of Public Offering of Common Stock
Intellia Therapeutics Announces Pricing of Public Offering of Common Stock

CAMBRIDGE, Mass., Nov. 30, 2022 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage...
By GlobeNewswire Inc. - 1 day ago

Intellia Therapeutics Announces Proposed Public Offering of Common Stock
Intellia Therapeutics Announces Proposed Public Offering of Common Stock

CAMBRIDGE, Mass., Nov. 30, 2022 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage...
By GlobeNewswire Inc. - 1 day ago

Intellia Therapeutics To Rally Around 143%? Plus Stifel Cuts PT On This Stock By 94%
Intellia Therapeutics To Rally Around 143%? Plus Stifel Cuts PT On This Stock By 94%

Chardan Capital boosted the price target on Intellia Therapeutics, Inc. (NASDAQ: NTLA) from $121 to...
By Benzinga - 2 weeks ago

Ultragenyx's (RARE) Q3 Earnings Miss Estimates, Revenues Up Y/Y
Ultragenyx's (RARE) Q3 Earnings Miss Estimates, Revenues Up Y/Y

Ultragenyx (RARE) reports a wider-than-expected loss in the third quarter. Revenues, though up year over...
By Zacks Investment Research - 4 weeks ago

Intellia Therapeutics Announces Third Quarter 2022 Financial Results and Highlights Recent Company Progress
Intellia Therapeutics Announces Third Quarter 2022 Financial Results and Highlights Recent Company Progress

CAMBRIDGE, Mass., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage...
By GlobeNewswire Inc. - 4 weeks ago

CRISPR Therapeutics (CRSP) Q3 Earnings Top, Sales Lag Estimates
CRISPR Therapeutics (CRSP) Q3 Earnings Top, Sales Lag Estimates

CRISPR Therapeutics (CRSP) third-quarter 2022 loss is narrower than expected, while sales miss estimates.
By Zacks Investment Research - 4 weeks ago

Repligen (RGEN) Beats Q3 Earnings Estimate, Ups 2022 Guidance
Repligen (RGEN) Beats Q3 Earnings Estimate, Ups 2022 Guidance

Repligen (RGEN) reports encouraging third-quarter results, with sales and earnings beating estimates. RGEN also raises...
By Zacks Investment Research - 4 weeks ago